FDA requires more data from Y-mabs

Following a meeting with Y-mabs, the US FDA have requested more data for the cancer drug omburtamab which the pharmaceutical firm is trying to get approval for.
Photo: Andrew Kelly/Reuters/Ritzau Scanpix
Photo: Andrew Kelly/Reuters/Ritzau Scanpix
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN

Recently, Danish biotech company Y-mabs Therapeutics and the US Food and Drug Administration (FDA) concluded a meeting which led to the FDA requiring further data concerning the firm's drug omburtamab.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading